Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07519278) titled 'Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Condition:
Healthy
Intervention:
Drug: Test formulation(pramipexole dihydrochloride extended-release tablets)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 16, 2017
Target Sample Size: 49
Countries of Recruitment:
China
To know more, visit...